Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlobeImmune’s Hep C Vaccine Posts Positive Phase II Data

This article was originally published in The Pink Sheet Daily

Executive Summary

GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.

You may also be interested in...



Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis

For GlobeImmune, the pharmacogenomic implications are important not only as a predictor of response to interferon, but also as a predictor of how the GI-5005 vaccine behaves. The company is tailoring its Phase III approach using that information.

Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis

For GlobeImmune, the pharmacogenomic implications are important not only as a predictor of response to interferon, but also as a predictor of how the GI-5005 vaccine behaves. The company is tailoring its Phase III approach using that information.

Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis

Positive Phase II results for GlobeImmune's immune-boosting hepatitis C vaccine GI-5005 were underscored at the European Association for the Study of the Liver meeting in Vienna April 17 by results from a newly available biomarker test that shows the therapy is most effective at clearing the virus from patients whose genetic status predicts little chance for complete recovery

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel